The Top Oncology Conferences to Attend in 2026

Looking for the most impactful oncology conferences in 2026? With hundreds of events competing for clinicians’ time, this guide highlights the top global meetings—like ASCO and ASH—alongside high-yield Binaytara conferences that deliver actionable insights, CME opportunities, and improved patient care outcomes.

When More Isn’t More: The Oncology Conference Plurality Issue

Although no one is keeping an exact record, there are, conservatively, hundreds of oncology educational conferences each year. It’s crucial to bring the latest advancements to clinicians given the complexity and breadth of cancer care, and at their best, conferences are a way for oncologists (and nurses, nurse practitioners, pharmacists, and cancer care stakeholders in all forms) to convene and benefit from the latest oncology research. And when the latest therapies and clinical data get a large-scale platform, practices benefit and patient outcomes steadily and meaningfully improve.

But clinicians have limited time to commit to continuing medical education, so they have to be strategic with which conferences they choose to attend. With thousands of conference hours to parse through, the landscape becomes confusing: in addition to delivering CME credits, which conferences convene top clinicians and investigators to offer genuinely practice-changing insights?

Most oncology practitioners know about giants like the ASCO Annual Meeting and ASH Annual Meeting. These events will see a combined attendance of around 70,000—a gathering size usually associated with Beyoncé concerts rather than oncology conferences. Even if you can attend one of these events, there are literally thousands of abstracts being presented in a matter of days, and a dizzying breadth of topics and events. The clinician looking to absorb it all has an uphill task ahead of them.

But if you’re looking for breaking clinical trial data, best-practice in-clinic guidelines, and the most important conversations in cancer care today, you’re not out of luck if you can’t make these events: we’re mapping the uncharted landscape. We’ve compiled a list of some of the most significant conferences in the United States, and a Binaytara conference that corresponds with each of those aims, audience, and outcomes—because we know that when oncologists and hematologists participate in continuing medical education, the entire cancer care ecosystem benefits.

What Are the Top Oncology Conferences in 2026?

1. If you're attending ASCO Annual Meeting → Best of Oncology™ 2026 (Seattle, Portland, El Paso, Boise, Shreveport, Omaha, Houston, Albuquerque)

They need no introduction: the American Society of Clinical Oncology (ASCO) will convene their five-day Annual Meeting in Chicago, IL starting in late May. This conference—the flagship event of one of oncology’s flagship institutions—is massive in scope. Estimated to draw over 40,000 attendees, the meeting will see major trial results announced across a range of oncology disciplines. Binaytara’s Best of Oncology™ series distills the clinical takeaways and most impactful trial outcomes from this meeting, bringing practice-changing insights to major cities and underserved rural locations alike.

“It is very important for patients and for doctors to have access to these conferences,” said Dr. Julie Graff, a Portland-area oncologist and conference chair.

2. If you're attending ASH Annual Meeting → 2026 National Summit on Hematologic Cancers

The American Society of Hematology (ASH) will convene its 68th annual meeting this December in Louisiana. As with ASCO, the conference stands out for its size and scope, with the Society projecting 30,000 attendees and 5,000 abstract submissions on leukemia, lymphoma, myeloma, and myelodysplastic syndromes. Meanwhile, the National Summit on Hematologic Cancers, convening in October 2026 in Nashville, TN, also promises to be a large gathering focusing on hematologic malignancies. The conference will feature $250,000 in hematology research funding disseminated via a Shark Tank-style research pitching competition. Each event in the two-day meeting will conclude with consensus recommendations for clinical scenarios lacking best-practice guidelines. For researchers and clinicians in the field of hematologic malignancies, both ASH and the National Summit on Hematologic Cancers prove a worthy destination.

3. If you're attending SITC → 6th Binaytara Precision Oncology Summit

The Society for Immunotherapy of Cancer (SITC) is holding their Annual Meeting this November 2026. SITC is the world’s largest member-driven organization organized around cancer immunotherapy—using the body's own immune functions (like T-cells or typical vaccine defense responses) to fight cancer. The SITC Annual Meeting discusses the latest breakthroughs therein. As immunotherapy and targeted/genomic therapies are deeply intertwined as far as novel treatments and research go, the 6th Binaytara Precision Oncology Summit maps closely onto SITC's immunotherapy emphasis. Precision oncology, one of the most significant advances in cancer medicine in the past three decades, sees specific biomarkers of a patient’s tumor drive therapy selection. The Binaytara conference is coming to San Francisco in September, and promises dedicated molecular tumor board sessions, discussions on AI-driven diagnostics, and, on the other side of the career continuum, an oral abstract presentation session from emerging investigators.

4. If you're attending SNO → 2026 Seattle Cellular Therapy Summit

Brain and central nervous system cancers are among the most difficult to treat. Despite this, the field is under-resourced, which makes the Society for Neuro-Oncology (SNO) an important venue. The conference will report on advances in glioblastoma, brain metastases, and related conditions. SNO’s ever-mobile annual meeting (2025 was in Hawai’i, and 2027 will be held in Arizona) brings together scientists, clinician researchers, community practitioners, allied health personnel, trainees, patient advocates, and industry partners to move toward improved prognoses.

Meanwhile, Binaytara’s 2026 Seattle Cellular Therapy Summit ties in one of the most important treatments for central nervous system cancers. Filtering for the buzziest topic at any conference, cellular therapies (think CAR-T, the immunotherapy that has transformed blood cancer treatment, for one), the conference instigates a sharply focused discussion on an important clinical topic. The conference’s planning committee consists of the regional and national drivers behind the evolution of cellular therapies, and the Summit maintains a balanced programmatic focus on both clinical breakthroughs and areas of clinical uncertainty. CAR-T and cellular therapies are increasingly relevant in neuro-oncology, and Seattle is a major hub for that research.

5. If you're attending ASTRO → Multidisciplinary Thoracic Oncology Conference

The American Society for Radiation Oncology (ASTRO) is holding their Annual Meeting this September. ASTRO’s mission is to advance the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving health care environment. Their Annual Meeting is a forefront event for radiation oncologists, nurses, and other stakeholders. But less obviously, one of ASTRO’s biggest topic areas is lung cancer. Binaytara’s Los Angeles-based Multidisciplinary Thoracic Oncology Conference—which focuses on advances in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma, and other thoracic malignancies—actually shares a core framework with ASTRO. In its aim to optimize outcomes for patients with thoracic malignancies, the November 2026 conference names radiation techniques as one of its multidisciplinary focuses.

6. If you're attending the AACR Pancreatic Cancer Conference → Rare Cancers Conference 2026

The American Association for Cancer Research (AACR), unsurprisingly, puts on a research-intensive Annual Meeting every year. They bring this same laboratory focus to their topic-specific meetings, including their Pancreatic Cancer Conference. Although a specialty conference, the four-day event is a landmark event for the community. Pancreatic cancer lands in the intersection of understudied and difficult to treat—meaning Binaytara’s Rare Cancer Conference offers a natural followup. The Rare Cancer Conference is founded on the principle that AACR’s Pancreatic Cancer Conference knows all too well: just because a condition is rare doesn’t mean it isn’t a significant burden. In fact, rare cancers may account for as much as a quarter of all cancer diagnoses, and lack the specialists to treat them.

7. If you're attending SABCS → 2026 Binaytara Northwest Women's Cancer Conference

The San Antonio Breast Cancer Symposium (SABCS) is perhaps the most prominent breast cancer-specific meeting, closely watched even by non-specialists. Held in December, it is historically the venue for landmark readouts in HER2+ disease, hormone receptor-positive breast cancer, and triple-negative breast cancer that directly reshape clinical practice. The Binaytara Northwest Women's Cancer Conference is a smaller, regional meeting—but, in a departure from dedicated breast or gynecologic symposia, the conference centers women with cancer in addition to its clinical focus on the cancer subgroup known as women’s cancers (breast, colorectal, uterine (endometrial), ovarian, and cervical). It boasts a dedicated clinical grounding, with a program promising novel therapeutic strategies, updated clinical trial results, and the evolving role of precision oncology in routine clinical practice. Both SABCS and Binaytara’s conference are important meetings at a time when breast and uterine cancers rank among the top ten highest-incidence cancers in the world.

Frequently Asked Questions About Oncology Conferences in 2026

1. What are the most important oncology conferences in 2026?

Some of the most prominent oncology conferences in 2026 include the ASCO Annual Meeting, ASH Annual Meeting, SITC Annual Meeting, ASTRO Annual Meeting, and SABCS. These large-scale events present cutting-edge research and attract global experts.

2. Are large oncology conferences like ASCO and ASH worth attending?

Yes, but they can be overwhelming due to their size, with tens of thousands of attendees and thousands of presentations. While they offer groundbreaking research, it can be challenging to absorb all the key insights in a short time.

3. What are the benefits of smaller or regional oncology conferences?

Smaller conferences—such as Binaytara events—often provide more focused, practical, and accessible education. They distill key findings from major meetings and emphasize real-world clinical applications, making them highly valuable for busy clinicians.

4. How do I choose the right oncology conference to attend?

Consider your specialty, learning goals, and available time. If you want exposure to the latest global research, large conferences are ideal. For practical insights and targeted discussions, smaller, specialized meetings may be more effective.

5. Do oncology conferences offer CME (Continuing Medical Education) credits?

Yes, most oncology conferences provide CME credits, helping clinicians maintain certification while staying updated on advancements in cancer care.

6. Are there oncology conferences focused on specific cancer types?

Absolutely. Conferences like SABCS focus on breast cancer, AACR’s Pancreatic Cancer Conference targets pancreatic cancer, and others specialize in hematologic malignancies or thoracic oncology.

7. Why is continuing medical education important in oncology?

Oncology is a rapidly evolving field with constant advancements in therapies, diagnostics, and clinical guidelines. Conferences play a critical role in keeping clinicians informed and improving patient outcomes.

8. Are there oncology conferences accessible to clinicians in underserved areas?

Yes. Some organizations, like Binaytara, bring conference insights to regional and underserved locations, improving access to high-quality oncology education.